Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OSBP | P22059 | 1/20 | 0.78 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.76 |
| ▸ | ST6GAL1 | P15907 | 2/20 | 0.75 |
| ▸ | INPP5D | Q92835 | 1/20 | 0.74 |
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.72 |
| ▸ | CASP7 | P55210 | 3/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.72 |
| ▸ | TP53 | P04637 | 2/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.72 |
| ▸ | BLM | P54132 | 2/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.72 |
| ▸ | VDR | P11473 | 2/20 | 0.72 |
| ▸ | USP2 | O75604 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.72 |
| ▸ | MDM4 | O15151 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epicoprosterol SCHEMBL11375007 | 1.00 | OSBP (0.78) | OSBPOSBP2CYP2C19CYP2D6ST6GAL1 | |
| Epicoprosterol SCHEMBL10066473 | 1.00 | OSBP (0.78) | OSBPOSBP2CYP2C19CYP2D6ST6GAL1 | |
| Epicoprosterol SCHEMBL18724866 | 1.00 | OSBP (0.78) | OSBPOSBP2CYP2C19CYP2D6ST6GAL1 | |
| Epicoprosterol SCHEMBL9906585 | 1.00 | OSBP (0.78) | OSBPOSBP2CYP2C19CYP2D6ST6GAL1 | |
| Epicoprosterol SCHEMBL24632942 | 1.00 | OSBP (0.78) | OSBPOSBP2CYP2C19CYP2D6ST6GAL1 | |
| Epicoprosterol SCHEMBL12549295 | 1.00 | OSBP (0.78) | OSBPOSBP2CYP2C19CYP2D6ST6GAL1 | |
| Epicoprosterol SCHEMBL25267973 | 1.00 | OSBP (0.78) | OSBPOSBP2CYP2C19CYP2D6ST6GAL1 | |
| Epicoprosterol SCHEMBL12214992 | 1.00 | OSBP (0.78) | OSBPOSBP2CYP2C19CYP2D6ST6GAL1 | |
| Epicoprosterol SCHEMBL21000320 | 1.00 | OSBP (0.78) | OSBPOSBP2CYP2C19CYP2D6ST6GAL1 | |
| Epicoprosterol SCHEMBL22018677 | 1.00 | OSBP (0.78) | OSBPOSBP2CYP2C19CYP2D6ST6GAL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333479-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-20240293551-A1 | USE OF ST-TYPE LIPID COMPOUNDS IN PREPARATION OF NUCLEIC ACID DELIVERY REAGENT AND RELATED PRODUCT | BEIJING BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD (CN) | 2024-09-05 | — | — | US | disclosed |
| EP-4378483-A1 | USE OF ST-TYPE LIPID COMPOUNDS IN PREPARATION OF NUCLEIC ACID DELIVERY REAGENT AND RELATED PRODUCT | Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (CN) | 2024-06-05 | — | — | EP | disclosed |
| EP-3529257-B1 | OXYSTEROLS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS INC (US) | 2023-05-10 | — | — | EP | disclosed |
| US-20210253872-A1 | METHOD FOR ESTABLISHING A FOULING RELEASE COATING SYSTEM | HEMPEL A/S (DK) | 2021-08-19 | — | — | US | disclosed |
| US-10690651-B2 | Small molecule metabolites for the diagnosis of bacterial vaginosis and assessment of disease risk | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2020-06-23 | — | — | US | disclosed |
| EP-3443054-B1 | PROCESS FOR PRODUCING A COMBUSTIBLE PRODUCT | INDUSTRIAL CHEMICALS GROUP LTD (GB) | 2020-01-29 | — | — | EP | disclosed |
| US-20190078032-A1 | PROCESS FOR PRODUCING A COMBUSTIBLE PRODUCT | INDUSTRIAL CHEMICALS GROUP LIMITED (GB) | 2019-03-14 | — | — | US | disclosed |
| EP-3231856-A1 | COMBUSTIBLE PRODUCT | Industrial Chemicals Group Limited (GB) | 2017-10-18 | — | — | EP | disclosed |
| WO-2009104649-A1 | SYNTHETIC GLYCOLIPID-CONTAINING LIPOSOMES | 片山化学工業株式会社 (JP) | 2009-08-27 | — | — | WO | disclosed |
| US-7544863-B2 | Transgenic plants containing altered levels of steroid compounds | MONSANTO TECHNOLOGY LLC (US) | 2009-06-09 | — | — | US | disclosed |
| US-20090029949-A1 | GPCR Ligands Identified by Computational Modeling | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-01-29 | — | — | US | disclosed |
| US-20080102405-A1 | Nitrogen-containing organic compound, resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. | 2008-05-01 | — | — | US | disclosed |
| US-20080064795-A1 | MATERIALS FREE OF ENDOCRINE DISRUPTIVE ACTIVITY | BITTNER GEORGE | 2008-03-13 | — | — | US | disclosed |
| US-7303760-B2 | Method for treating multi-drug resistant tumors | ALZA CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-7276248-B2 | Conjugate having a cleavable linkage for use in a liposome | ALZA CORPORATION (US) | 2007-10-02 | — | — | US | disclosed |
| US-20070122750-A1 | Salt suitable for an acid generator and a chemically amplified resist composition containing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-05-31 | — | — | US | disclosed |
| US-20070122750-A1 | Salt suitable for an acid generator and a chemically amplified resist composition containing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-05-31 | — | — | US | disclosed |
| US-20070122750-A1 | Salt suitable for an acid generator and a chemically amplified resist composition containing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080102405-A1 | Nitrogen-containing organic compound, resist composition and patterning process | MDM4, MUS81, NOP2 | OSBP 923/4885OSBP2 982/4885CYP2C19 1742/4885 |
| US-20240293551-A1 | USE OF ST-TYPE LIPID COMPOUNDS IN PREPARATION OF NUCLEIC ACID DELIVERY REAGENT AND RELATED PRODUCT | POLRMT, LIPC, POLM | OSBP 718/4885OSBP2 1512/4885CYP2C19 2589/4885 |
| US-20250333479-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | OSBP 2427/4885OSBP2 906/4885CYP2C19 4872/4885 |
| US-20070122750-A1 | Salt suitable for an acid generator and a chemically amplified resist composition containing the same | HCN3, NHERF1, HCN4 | OSBP 2292/4885OSBP2 2829/4885CYP2C19 951/4885 |
| US-20090029949-A1 | GPCR Ligands Identified by Computational Modeling | LPAR3, LPAR2, LPAR1 | OSBP 520/4885OSBP2 397/4885CYP2C19 4347/4885 |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | OSBP 2384/4885OSBP2 987/4885CYP2C19 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.